REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.

2. Karabajakian A, Toussaint P, Neidhardt EM, Paulus V, Saintigny P, et al. Chemotherapy for recurrent/metastatic head and neck cancers. Anticancer Drugs 2017;28:357-61.

3. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 2018;81:45-51.

4. Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393:156-67.

5. Ferris RL, Even C, Haddad R, Tahara M, Goswami T, et al. Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle. J Immunother Cancer 2015;3:P150.

6. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, et al. KEYNOTE-048: Phase 3 study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Available from: https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/KEYNOTE-048-Phase-3-study-of-first-line-pembrolizumab-P-for-recurrent-metastatic-head-and-neck-squamous-cell-carcinoma-R-M-HNSCC. [Accessed on 23 Oct 2019].

7. Sun XS, Sire C, Tao Y, Martin L, Alfonsi M, et al. A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): first results of the GORTEC 2015-01 “PembroRad” trial. J Clin Oncol 2018;36:6018.

8. Uppaluri R, Zolkind P, Lin T, Nussenbaum B, Jackson RS, et al. Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2017;35:6012.

9. Ferris RL, Gonçalves A, Baxi SS, Martens U, Gauthier H, et al. LBA46An open-label, multicohort, phase 1/2 study in patients with virus-associated cancers (CheckMate 358): safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol 2017;28.

10. Economopoulou P, Kotsantis I, Psyrri A. The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. ESMO Open 2016;1:e000122.

11. Cho BC, Daste A, Ravaud A, Salas S, Isambert N, et al. 1048OM7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: results from a phase I cohort. Ann Oncol 2018;29.

12. André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, et al. Anti-NKG2A mAb is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell 2018;175:1731-43.e13.

13. Cohen EEW, Harrington KJ, Hong DS, Mesia R, Brana I, et al. 1044OA phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results. Ann Oncol 2018;29:mdy287.

14. Cohen EEW, Nabell L, Wong DJL, Day TA, Daniels GA, et al. Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2019;37:6039.

15. Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, et al. Epacadostat plus Pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037). J Clin Oncol 2018:JCO2018789602.

16. Taylor MH, Rasco DW, Brose MS, Vogelzang NJ, Richey SL, et al. A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2018;36:6016.

17. Bell RB, Duhen R, Leidner RS, Curti BD, Ballesteros-Merino C, et al. Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squamous cell carcinoma. J Clin Oncol 2018;36:6011.

18. Ogasawara M, Miyashita M, Yamagishi Y, Ota S. Phase I/II pilot study of Wilms’ tumor 1 peptide-pulsed dendritic cell vaccination combined with conventional chemotherapy in patients with head and neck cancer. Ther Apher Dial 2019;23:279-88.

19. Haddad R, Concha-Benavente F, Blumenschein G, Fayette J, Guigay J, et al. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: a subgroup analysis of a randomized phase 3 clinical trial. Cancer 2019;125:3208-18.

20. Saâda-Bouzid E, Defaucheux C, Karabajakian A, Palomar Coloma V, Servois V, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2017;28:1605-11.

21. Foster CC, Kochanny S, Khattri A, Acharya R, Dekker A, et al. Association of immune-related adverse events (irAEs) with improved response, progression-free survival, and overall survival for patients with metastatic head and neck cancer receiving anti-PD-1 therapy. J Clin Oncol 2018;36:6014.

22. De Cecco L, Nicolau M, Giannoccaro M, Daidone MG, Bossi P, et al. Head and neck cancer subtypes with biological and clinical relevance: meta-analysis of gene-expression data. Oncotarget 2015;6:9627-42.

23. Hanna GJ, Liu H, Jones RE, Bacay AF, Lizotte PH, et al. Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol 2017;67:61-9.

24. Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, et al. Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy. Clin Cancer Res 2017;23:5729-36.

25. Kirtane K, Muzaffar J, Slebos R, Chung CH. Association between human papillomavirus (HPV) status and duration of response of anti-programmed cell death protein-1 (PD-1) inhibitors in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2019;37:6044.

26. Foster CC, Kochanny S, Khattri A, Acharya R, Dekker A, et al. Association of a baseline neutrophil-to-lymphocyte ratio (NLR) with progression-free and overall survival in head and neck cancer patients receiving anti-PD-1 therapy. J Clin Oncol 2018;36:6038.

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/